Zydus Lifesciences has received tentative approval from the FDA to market its Amantadine Extended-Release Capsules in the United States. Amantadine is indicated for the treatment of dyskinesia (sudden uncontrolled movements) in patients with Parkinsons disease who are treated with levodopa therapy, with or without dopaminergic medicines. The pharmaceutical company said that...